The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 5, 2017, Pages 525-532

  Wijarnpreecha, Karn ^a   Boonpheng, Boonphiphop ^b   Thongprayoon, Charat ^a   Jaruvongvanich, Veeravich ^c   Ungprasert, Patompong ^d,e  

^a BASSETT MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d MAYO CLINIC   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atrial arrhythmia; Atrial fibrillation; Meta analysis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ARTICLE; ATRIAL FIBRILLATION; COMPARATIVE STUDY; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; NONALCOHOLIC FATTY LIVER; SYSTEMATIC REVIEW; COMPLICATION;

ATRIAL FIBRILLATION; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85028588989     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2017.08.001     Document Type: Article

References (36)

1. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:9 (2004), 1042–1046.
2. Kannel, W.B., Abbott, R.D., Savage, D.D., McNamara, P.M., Epidemiologic features of chronic atrial fibrillation: the Framingham study. New Engl J Med 306:17 (1982), 1018–1022.
3. Miller, J.D., Aronis, K.N., Chrispin, J., Patil, K.D., Marine, J.E., Martin, S.S., et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol 66:25 (2015), 2899–2906.
4. Watanabe, H., Watanabe, T., Sasaki, S., Nagai, K., Roden, D.M., Aizawa, Y., Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158:4 (2009), 629–636.
5. Woeber, K.A., Thyrotoxicosis and the heart. New Engl J Med 327:2 (1992), 94–98.
6. Adams, L.A., Anstee, Q.M., Tilg, H., Targher, G., Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:6 (2017), 1138–1153.
7. Ballestri, S., Lonardo, A., Bonapace, S., Byrne, C.D., Loria, P., Targher, G., Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:7 (2014), 1724–1745.
8. Karajamaki, A.J., Patsi, O.P., Savolainen, M., Kesaniemi, Y.A., Huikuri, H., Ukkola, O., Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PloS One, 10(11), 2015, e0142937.
9. Markus, M.R., Meffert, P.J., Baumeister, S.E., Lieb, W., Siewert, U., Schipf, S., et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: The Study of Health in Pomerania (SHIP). Atherosclerosis 245 (2016), 123–131.
10. You, S.C.S.Y.P, Kim, T.-H., Uhm, J.-S., Pak, H.-N., Lee, M.-H., Joung, B., Non-alcoholic fatty liver disease is independently associated with new onset atrial fibrilation: a Nationwide cohort study in Korea. JACC, 67(13), 2016, 854.
11. Targher, G., Mantovani, A., Pichiri, I., Rigolon, R., Dauriz, M., Zoppini, G., et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci 125:6 (2013), 301–309.
12. Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PloS One, 8(2), 2013, e57183.
13. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:9 (2010), 603–605.
14. Herzog, R., Alvarez-Pasquin, M.J., Diaz, C., Del Barrio, J.L., Estrada, J.M., Gil, A., Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health, 13, 2013, 154.
15. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7:3 (1986), 177–188.
16. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
17. Ajmal, M.R., Yaccha, M., Malik, M.A., Rabbani, M.U., Ahmad, I., Isalm, N., et al. Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-alpha. Indian Heart J 66:6 (2014), 574–579.
18. Lee, J., Yoon, K., Ryu, S., Chang, Y., Kim, H.R., High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PloS One, 12(2), 2017, e0172666.
19. Maleki, I., Rastgar, A., Hosseini, V., Taghvaei, T., Rafiei, A., Barzin, M., et al. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci 18:11 (2014), 1583–1590.
20. Foroughi, M., Maghsoudi, Z., Khayyatzadeh, S., Ghiasvand, R., Askari, G., Iraj, B., Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res, 5, 2016, 28.
21. Ndumele, C.E., Nasir, K., Conceicao, R.D., Carvalho, J.A., Blumenthal, R.S., Santos, R.D., Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arteriosclerosis Thromb Vascular Biol 31:8 (2011), 1927–1932.
22. Aviles, R.J., Martin, D.O., Apperson-Hansen, C., Houghtaling, P.L., Rautaharju, P., Kronmal, R.A., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108:24 (2003), 3006–3010.
23. Chung, M.K., Martin, D.O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C.A., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:24 (2001), 2886–2891.
24. Guo, Y., Lip, G.Y., Apostolakis, S., Inflammation in atrial fibrillation. J Am Coll Cardiol 60:22 (2012), 2263–2270.
25. Harada, M., Van Wagoner, D.R., Nattel, S., Role of inflammation in atrial fibrillation pathophysiology and management. Circulation 79:3 (2015), 495–502.
26. Liu, Y.C., Hung, C.S., Wu, Y.W., Lee, Y.C., Lin, Y.H., Lin, C., et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PloS One, 8(4), 2013, e61803.
27. Newton, J.L., Pairman, J., Wilton, K., Jones, D.E., Day, C., Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Autonom Res 19:6 (2009), 319–326.
28. Sun, W., Zhang, D., Sun, J., Xu, B., Sun, K., Wang, T., et al. Association between non-alcoholic fatty liver disease and autonomic dysfunction in a Chinese population. QJM 108:8 (2015), 617–624.
29. Agarwal, S.K., Norby, F.L., Whitsel, E.A., Soliman, E.Z., Chen, L.Y., Loehr, L.R., et al. Cardiac autonomic dysfunction and incidence of atrial fibrillation: results from 20 years follow-up. J Am Coll Cardiol 69:3 (2017), 291–299.
30. Park, H.W., Shen, M.J., Lin, S.F., Fishbein, M.C., Chen, L.S., Chen, P.S., Neural mechanisms of atrial fibrillation. Curr Opin Cardiol 27:1 (2012), 24–28.
31. Shen, M.J., Zipes, D.P., Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 114:6 (2014), 1004–1021.
32. Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62:1 Suppl. (2015), S47–S64.
33. Petta, S., Argano, C., Colomba, D., Camma, C., Di Marco, V., Cabibi, D., et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 62:4 (2015), 928–933.
34. Eldar, M., Canetti, M., Rotstein, Z., Boyko, V., Gottlieb, S., Kaplinsky, E., et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 97:10 (1998), 965–970.
35. Santhanakrishnan, R., Wang, N., Larson, M.G., Magnani, J.W., McManus, D.D., Lubitz, S.A., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133:5 (2016), 484–492.
36. Wong, C.K., White, H.D., Wilcox, R.G., Criger, D.A., Califf, R.M., Topol, E.J., et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 140:6 (2000), 878–885.